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A R T I C L E  I N F O   




Type 2 Diabetes 
Nested case-control study 
A B S T R A C T   
Perfluoroalkyl substances (PFAS) are widespread persistent environmental pollutants. There is evidence that 
PFAS induce metabolic perturbations in humans, but underlying mechanisms are still unknown. In this 
exploratory study, we investigated PFAS-related plasma metabolites for their associations with type 2 diabetes 
(T2D) to gain potential mechanistic insight in these perturbations. 
We used untargeted LC-MS metabolomics to find metabolites related to PFAS exposures in a case-control study 
on T2D (n = 187 matched pairs) nested within the Västerbotten Intervention Programme cohort. Following 
principal component analysis (PCA), six PFAS measured in plasma appeared in two groups: 1) perfluorononanoic 
acid, perfluorodecanoic acid and perfluoroundecanoic acid and 2) perfluorohexane sulfonic acid, per-
fluorooctane sulfonic acid and perfluorooctanoic acid. Using a random forest algorithm, we discovered metab-
olite features associated with individual PFAS and PFAS exposure groups which were subsequently investigated 
for associations with risk of T2D. 
PFAS levels correlated with 171 metabolite features (0.16 ≤ |r| ≤ 0.37, false discovery rate (FDR) adjusted p 
< 0.05). Out of these, 35 associated with T2D (p < 0.05), with 7 remaining after multiple testing adjustment 
(FDR < 0.05). PCA of the 35 PFAS- and T2D-related metabolite features revealed two patterns, dominated by 
glycerophospholipids and diacylglycerols, with opposite T2D associations. The glycerophospholipids correlated 
positively with PFAS and associated inversely with risk for T2D (Odds Ratio (OR) per 1 standard deviation (1-SD) 
increase in metabolite PCA pattern score = 0.2; 95% Confidence Interval (CI) = 0.1–0.4). The diacylglycerols 
also correlated positively with PFAS, but they associated with increased risk for T2D (OR per 1-SD = 1.9; 95% CI 
= 1.3–2.7). These results suggest that PFAS associate with two groups of lipid species with opposite relations to 
T2D risk.   
1. Introduction 
Perfluoroalkyl substances (PFAS) comprise a large group of chem-
icals used in a variety of technological applications like textile or leather 
treatment, surfactants and food packaging to make them e.g. non-stick 
and stain repellent. The half-life of PFAS in humans is 3–5 years (Cala-
fat et al., 2007; Olsen et al., 2007) and bioaccumulative properties of 
PFAS increase by chain length and sulfonation with the strongest bio- 
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accumulative properties for long-chain and sulfonated PFAS (Conder 
et al., 2008). Exposure occurs mainly via consumption of fish and 
contaminated drinking water (Haug et al., 2010; Stubleski et al., 2017), 
although house dust and contact with products containing PFAS could 
contribute (Haug et al., 2011; Vestergren and Cousins, 2009; Strynar 
and Lindstrom, 2008). PFAS have been hypothesized to influence 
metabolic control mechanisms involved in the development of type 2 
diabetes (T2D) (Sunderland et al., 2019), a major global health problem, 
characterised by insulin resistance of target tissues and reduced insulin 
secretion by the pancreatic β-cells (Olokoba et al., 2012). 
The chemical structure of PFAS has homology with that of fatty acids 
and could interfere with fatty acid oxidative or endocrine pathways 
(Sheng et al., 2018; Kar et al., 2017; Jensen and Leffers, 2008). Fore-
most, in vitro studies show that PFAS are ligands for peroxisome 
proliferator-activated receptors (PPARs) α, γ (Wolf et al., 2008b; Rosen 
et al., 2017; Vanden Heuvel et al., 2006) and β/δ with different po-
tencies depending on carbon chain length and terminal functional group 
(Li et al., 2019; Wolf et al., 2008a). PPARs regulate glucose and lipid 
metabolism and are involved in adipogenesis, fat storage and inflam-
mation (Bocher et al., 2002; Lefebvre et al., 2006; Poynter and Daynes, 
1998). In addition, PFAS may influence β-cell viability (Maillard et al., 
2012, 2008), disrupt thyroid hormones (Lee and Choi, 2017) and sex 
steroid hormone biosynthesis (Zhao et al., 2010; Boujrad et al., 2000; Shi 
et al., 2010, 2007; Lau et al., 2007), which implies that there may be sex- 
specific effects. Although some animal data support more of a potential 
beneficial effect of PFAS on glucose and lipid homeostasis (Yan et al., 
2015; Bijland et al., 2011; Kees et al., 1992), the epidemiological evi-
dence is limited and inconsistent, showing direct (He et al., 2018; Sun 
et al., 2018), null or even inverse associations with T2D (Donat-Vargas 
et al., 2019a; MacNeil et al., 2009; Conway et al., 2016; Karnes et al., 
2014). Our previous study, based on the present study population, 
assessing PFAS exposures with T2D risk without including the metab-
olome, found nominal inverse associations of PFAS with insulin resis-
tance and T2D risk, possibly explained by PFAS activation of PPARs 
(Donat-Vargas et al., 2019a). 
However, the relevant metabolic and molecular pathways involved 
in T2D development that may be affected by PFAS have not been fully 
elucidated. Thus, to gain more insight in the PFAS-T2D relation, 
metabolomics can be a useful tool (Wild, 2005; Rattray et al., 2018) as 
the presence and concentration of metabolites directly reflects the un-
derlying biochemical activity (Kim et al., 2016). So far, few studies have 
investigated metabolites associated with PFAS (Salihovic et al., 2019), 
of which two were in children (Alderete et al., 2019; Kingsley et al., 
2019) and one related to pregnancy (Hu et al., 2019). These studies 
indicated mainly perturbations in lipid and fatty acid metabolism and 
also found distinctive metabolic profiles for different PFAS (Salihovic 
et al., 2019), nevertheless, none investigated associations with T2D risk. 
Thus, we analysed untargeted metabolomics data from a T2D case- 
control study nested in a population-based prospective cohort. Our ob-
jectives were to discover metabolites related to PFAS exposures, explore 
potential differences in metabolic profiles of six chemically different 
PFAS, and to investigate whether PFAS-related metabolite patterns were 
associated with risk of developing T2D. 
2. Materials and methods 
2.1. Study population 
This nested case-control study from the Västerbotten Intervention 
Programme cohort included participants that had donated overnight 
fasting blood samples to the biobank on two occasions on average 10 
(±4.4) years apart (of which at least the first was prior to the case 
diagnosis) (Donat-Vargas et al., 2019a). The Västerbotten Intervention 
Programme, initiated 1985, invited all residents in Västerbotten County 
in Northern Sweden for health screening and blood sampling when they 
turned 40, 50 and 60 years. This study includes baseline data 1990–2003 
and follow-up data 2000–2013. Participation rate exceeded 56%, being 
often around 70%, and 90.5% also donated blood samples (Norberg 
et al., 2010). Incident diabetes cases were identified in the DiabNorth 
register (last update in 2008), which had a participation rate of 70% of 
VIP participants diagnosed with diabetes, (Rolandsson et al., 2012) and 
were diagnosed according to WHO recommendations and analysis of 
autoantibodies (Rolandsson et al., 2012). The average time from base-
line blood sampling to diabetes diagnosis was 8.2 years. Diabetes cases 
were individually matched with controls based on age, sex and date of 
blood draw. PFAS and metabolites were measured in 374 participants at 
baseline and follow-up (187 diabetes case-control pairs). All 374 par-
ticipants were included in an initial exploratory phase where PFAS- 
related metabolite features were discovered, as indicated in Fig. 1. For 
the association analyses between PFAS-related metabolite features and 
T2D, analysis was restricted to 124 T2D case-control pairs (excluded 
matched pairs if cases had an unclear diabetes diagnosis (n = 34 pairs) 
or had diabetes at baseline (n = 21 pairs) and if controls had possible 
diabetes (n = 8 pairs)) (Donat-Vargas et al., 2019a). 
Participation information, collected via questionnaires, included 
marital status, attained education, smoking status, body mass index 
(BMI) and physical activity (as determined by Cambridge index for 
physical activity). Based on a validated food frequency questionnaire, 
we retrieved information on red/processed meat, fish (g/day per 1000 
kcal) and alcohol consumption (g/day) (Johansson et al., 2001, 2002; 
Nettleton et al., 2013). Informed consent was obtained from all partic-
ipants. The study protocol was approved by the regional ethics review 
boards in Umeå and Uppsala, Sweden (Dnr 2013/414-31, 2014/147-32 
M and 2014/011). 
2.2. Targeted LC-MS PFAS measurements 
PFAS concentrations were measured in plasma samples from base-
line and follow-up through targeted liquid chromatography-triple 
quadrupole mass spectrometry (LC-MS/MS) as previously described 
(Koponen et al., 2013). Six different PFAS compounds had detectable 
concentrations: perfluorohexane sulfonic acid (PFHxS), perfluorooctane 
sulfonate (PFOS), perfluorooctanoic acid (PFOA), perfluorononanoic 
acid (PFNA), perfluorodecanoic acid (PFDA) and perfluoroundecanoic 
acid (PFUnDA). Concentrations below the limit of quantitation (LOQ) 
were set to the LOQ/2 = 0.075 ng/mL for 26% of the subjects in PFDA 
and 42% in PFUnDA (Donat-Vargas et al., 2019a; Richardson and 
Ciampi, 2003). 
2.3. Untargeted LC-MS metabolite profiling 
Untargeted LC-quadrupole time of flight (qTOF)-MS metabolic 
profiling was performed on baseline and follow-up plasma samples (Shi 
et al., 2018b). Data acquisition, corrections and normalizations were 
performed previously and have been described elsewhere (Brunius et al., 
2016; Shi et al., 2017). In brief, de-proteinised fasting heparin plasma 
samples were analysed by LC-qTOF-MS (Agilent Technologies, United 
States) on reverse phase and hydrophilic interaction liquid chromatog-
raphy columns in both positive and negative ionisation modes. The 
MassHunter Acquisition B.04.00 software (Agilent Technologies) was 
used for data acquisition. Raw data was converted to mzXML format and 
deconvolution was performed (‘XCMS’ R package) (Shi et al., 2017). The 
stability of the instrumental analysis was monitored by quality control 
samples (batch-specific pooled aliquots of the study samples and a long- 
term reference sample were injected at the beginning, end and regularly 
throughout the injection sequence). Measurement drift was calculated 
per batch by a cluster-based approach using batch-specific quality 
control samples with signal correction performed per cluster if resulting 
in improved measurement homogeneity among long-term reference 
samples (‘batchCorr’ R package) (Brunius et al., 2016). Features were 
over-all retained if they passed QC test (CV < 0.3) in at least five out of 
the eight analytical batches (Supplementary Material of L. Shi et al. 
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2018 (Shi et al., 2018a)). Missing values were replaced with values 
selected at random from a normal distribution between 0 and the lowest 
measured peak intensity for each metabolite feature under the 
assumption of missing not at random due to low concentration. Poorly 
retained lipids in hydrophilic interaction chromatography (retention 
time < 70 s) were removed, as these were better represented in reverse 
phase. We use the term metabolite feature to refer to a molecular entity 
with a unique mass to charge ratio and retention time as measured by 
LC-MS. We putatively annotated six metabolite features as possible PFAS 
(Supplementary Table 1), which were excluded from the metabolomics 
dataset in order not to bias data models by being included both as in-
dependent and dependent variables. 
2.4. Statistical analysis 
A flow-chart of the analytical procedure is presented in Fig. 1. To 
discover metabolite features related not only to individual PFAS expo-
sures, but also PFAS exposure groups, we performed an orthogonally 
(varimax) rotated principal component analysis (PCA) on individual 
square root-transformed PFAS scaled to unit variance. We obtained two 
PFAS groups through manual inspection of the first two principal 
component (PC) loadings (eigenvalue > 1). The two PFAS groups and 
the individual PFAS were later tested for their correlations with PFAS- 
related metabolite features, to investigate whether the PFAS groups 
associated with similar metabolic alterations as the individual PFAS. We 
filtered out the majority of metabolite features likely not associated with 
PFAS by sparse partial least squares regression using four components 
and the metabolomics data as the predictor variables and each of 
Fig. 1. Flow chart of the analytical study design divided in selection of PFAS-related features (top) and associations between PFAS-related features and risk of T2D 
(bottom). PFAS-related features were discovered using the random forest algorithm in step 1 and validated in step 2 for the reduced sample population at baseline 
after inclusion of confounders. Subsequently, the validated features were investigated for their prospective associations with T2D. Abbreviations: Principal 
Component Analysis (PCA) and Partial Least Squares (PLS). 
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individual square root-transformed PFAS concentrations and two PFAS 
groups as response variables. The arbitrary choice of four components 
allowed for a compromise between modelling complexity and parsi-
mony and reduced the number of features from 24,758 to approximately 
4000 and was performed primarily to improve the computational per-
formance in the subsequent predictive modelling: The pre-filtered 
metabolomics data were entered as predictor data and processed using 
a random forest model within a repeated double-cross validation 
framework incorporated with unbiased variable selection (R package 
MUVR (Shi et al., 2019a), tutorial available on https://gitlab. 
com/CarlBrunius/MUVR), using each of the individual square root- 
transformed PFAS concentrations and PFAS groups (n = 2) as 
response variables. In order to assess modelling performance, permu-
tation analysis was performed (n = 50, p < 0.001) (Lindgren et al., 
1996), parameter settings for the random forest models and permutation 
analyses are described in Supplementary Table 2. Moreover, to exclude 
metabolite features that likely originated from sex or baseline versus 
follow-up measurement differences, we tested the robustness of the 
discovered metabolite features associated with PFAS by a series of 
similar analyses, stratified by sex and measurement occasion. Those 
metabolite features that were present both in the overall model and in at 
least one of the sex and measurement stratified models, were further 
validated using partial Spearman correlation with PFAS levels at the 
baseline measurement while adjusting for the following potential con-
founding factors: sex, age, sample year, marital status, education, 
smoking status, physical activity and case-control status. PFAS were 
square root-transformed and metabolite features were square root- 
transformed as well as standardized prior to the correlation analysis 
and p-values were False Discovery Rate adjusted for multiple testing 
(FDR < 0.05). 
In the second step, PFAS-related metabolite features were tested for 
their individual prospective associations with T2D risk using conditional 
logistic regressions, with standardized square root-transformed metab-
olite features as the independent variables. In model 1, the analyses 
were adjusted for age, sex and sample year, marital status, education, 
smoking status and physical activity, and in model 2 additionally for 
fish-, red/processed meat- and alcohol consumption and BMI (Donat- 
Vargas et al., 2019a). Resulting p-values from all models were adjusted 
for multiple testing (FDR < 0.05). Odds ratio (OR) is presented per 1- 
standard deviation (SD) increase. The likelihood for discovering T2D- 
related metabolite features amongst the PFAS-related metabolite fea-
tures was assessed using the hypergeometric test (p < 0.05). 
In order to investigate intercorrelations between PFAS- and T2D- 
related metabolite features, a PCA was constructed based on the 35 
selected metabolite features associated with T2D (p < 0.05). Correla-
tions between PCs (n = 3, eigenvalue > 2) and individual PFAS, PFAS 
groups, food intakes (i.e. fish, red/processed meat), alcohol consump-
tion, BMI and HOMA-IR were analysed using partial Spearman corre-
lation analysis adjusted for sex, age, sample year, marital status, 
education, smoking status, physical activity and case-control status. 
Associations between PC scores and T2D risk were analysed using con-
ditional logistic regression adjusted for covariates according to model 1 
and model 2 (as above). In a sensitivity analysis, we also investigated 
associations between PC scores and T2D risk while stratifying for sex. 
OR is presented per 1-SD increase in the pattern score. The associations 
between T2D- and PFAS-related metabolite feature patterns, the PFAS 
levels and diet with T2D risk were displayed in a triplot (Schillemans 
et al., 2019) (R package Triplot, tutorial available on https://gitlab. 
com/CarlBrunius/triplot). Briefly, the triplot is a visualization tool 
that facilitates interpretation of exposures, the metabolome and disease 
risk data. It presents loadings of metabolite features in 2 PCs (in black), 
whilst superimposing the correlations between the PCs and the PFAS 
levels or diet components (in blue) as well as the associations between 
the PCs and T2D risk (in red). Thus, metabolites, PFAS levels/diet 
components and T2D risk pulling in the same axis in the triplot figure are 
positively correlated/directly associated, whereas opposite axis are 
negatively correlated/inversely associated. 
These findings were validated in a second dataset containing par-
ticipants from the same case-control study with similar background 
characteristics (Supplementary Table 3), but with only one measure-
ment (baseline) and without PFAS measurements (N = 598) (Shi et al., 
2018a). PC scores for the PFAS and T2D-related metabolite feature 
patterns were predicted in the validation dataset based on the PCA of the 
original dataset (described above) and then used in a conditional logistic 
regression with T2D risk. 
To avoid confusion, the term “group” refers to exposure groups ob-
tained from the PCA on PFAS, whereas the term “pattern” refers to 
metabolite feature patterns obtained from the PCA on the PFAS- and 
T2D-related metabolite features. All statistical analyses were performed 
using R software version 3.4.3 (R Core Team, Vienna, Austria) (R Core 
Team, 2017). 
2.5. Metabolite identification 
The metabolite annotation is reported in Supplementary Table 4, 
following the Metabolomics Standards Initiative (MSI) reporting criteria 
for the confidence level. Auto-MS/MS data was only available for a few 
of the selected metabolite feature peaks, some of these could be matched 
to literature based on accurate mass and product ion spectrum (level 2) 
(Shi et al., 2018b, 2019b; Hanhineva et al., 2014). Other metabolite 
features associated with PFAS and T2D were putatively annotated for 
compound class based on m/z (mass tolerance < 20 ppm) and retention 
time using matching against online databases (level 3). Unknown 
compounds were presented as “analytical mode _ m/z @ retention time” 
(level 4). 
3. Results 
3.1. Population and PFAS 
Total study population characteristics at baseline are described in 
Table 1. 
Differences in characteristics and PFAS concentrations between cases 
and controls at baseline and follow-up as well as the PFAS in-
tercorrelations are described in our previous papers (Donat-Vargas et al., 
2019a, 2019b). In brief, T2D cases had somewhat higher BMI and 
physical activity, but lower PFAS concentrations (except for PFNA) 
compared to the controls (Donat-Vargas et al., 2019a). High correlations 
were found between PFOS and PFOA as well as between PFNA, PFDA 
Table 1 
Baseline main characteristics of the total study population (N = 374).  
Characteristics Total Study Population 
(N = 374) 
Femalesa, n (%) 172 (46) 
Agea (years) 46 ± 6 
Body Mass Index (kg/m2) 27 ± 4 
Education, n (%)  
>12 yrs. 270 (72) 
Smoking status, n (%)  
Former 144 (39) 
Current 86 (23) 
Physical activityb, n (%)  
Inactive 201 (54) 
Fish (g/day/1000 kcal) 10.0 ± 7.8 
Meat (g/day/1000 kcal) 50.3 ± 21.2 
Alcohol consumption, n (%)  
0.1–5 (g/day) 260 (70) 
5–15 (g/day) 87 (23) 
>15 (g/day) 6 (2) 
Note: Continuous variables are given as mean ± SD and categorical variables 
are given as number (percentage). 
a Matching factors for case-control pairs. 
b Cambridge index for physical activity. 
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and PFUnDA (Donat-Vargas et al., 2019a). In addition to the previously 
observed results where PFOS and PFOA had higher concentrations at 
baseline, whereas PFNA and PFDA seemed higher at follow-up (Donat- 
Vargas et al., 2019b), a tendency for higher PFAS concentrations was 
observed in males compared to females, with exception of PFUnDA 
(Fig. 2). The PCA of the six PFAS showed that two PCs accounted for 
73% of the variance. High loadings were observed for the long-chain 
PFDA, PFNA and PFUnDA in PC1 (henceforth referred to as LC_PFAS) 
and for the shorter-chain PFHxS, PFOS and PFOA in PC2 (SC_PFAS) 
(Supplementary Table 5). 
3.2. PFAS-related metabolite features 
The number of metabolite features observed per individual PFAS and 
PFAS group after each analysis step is presented in Table 2. We found 
290 unique metabolite features related to one or more PFAS in the 
multivariate random forest models (permutation analysis p < 0.001), 
after filtering out those features likely to be selected because of sex or 
time of measurement differences alone (Supplementary Table 6). Out of 
these 290 metabolite features, 171 correlated with individual PFAS at 
baseline in the selected population (n = 124) after adjustment for con-
founders (0.16 ≤| r |≤ 0.37, FDR < 0.05). Among them, a majority of 
metabolite features were associated with PFNA, PFDA, PFUnDA or their 
affiliated LC_PFAS group (Table 2). 
3.3. PFAS and T2D-related metabolite features 
Among the 171 PFAS-associated metabolite features, 35 associated 
with T2D adjusted for matching factors, marital status, education, 
smoking status and physical activity in model 1, (Supplementary Fig. 1), 
but only 13 remained after full multivariable-adjustment in model 2 
(model 1 additionally adjusted for fish-, red/processed meat- and 
alcohol consumption and BMI) (Fig. 3). After adjustment for multiple 
testing, 7 metabolite features remained in model 1 (hypergeometric p <
0.0025; Supplementary Table 7–8), but only 1 in model 2 (hypergeo-
metric p = 0.45; Supplementary Table 7–8). One metabolite annotated 
as gamma-butyrobetaine (GBB) correlated negatively with PFAS but 
associated inversely with T2D risk. Other features with strong associa-
tions to both PFAS and T2D risk were annotated to compound classes of 
Fig. 2. PFAS concentrations (ng/mL) in the entire study population (n = 374) at baseline and follow-up for males and females. All PFAS, except PFUnDA, had higher 
concentrations in males compared to females. 
Table 2 
Number of metabolite features (maximum model) related per individual PFAS or 
PFAS pattern exposures and model performance by prediction fitness and per-















fitnessa, b  
R2 Q2 
Individual PFAS 
PFOS 150 0.415 0.347 36 19 
PFOA 150 0.339 0.234 45 14 
PFHxS 140 0.417 0.336 35 18 
PFDA 220 0.376 0.307 81 66 
PFNA 200 0.385 0.315 72 62 
PFUnDA 180 0.334 0.243 78 59 
PFAS patterne 
LC_PFAS 250 0.42 0.357 82 65 
SC_PFAS 100 0.465 0.38 27 13  
a R2 indicates goodness of fit of the model. Q2 indicates predictive ability of 
the model. 
b Permutation p < 0.001 from permutation analysis (n = 50) for weakest two 
models (PFOA and PFUnDA). 
c I.e. metabolite features selected from the full sample model (males, females 
and both measurements) that also occur in at least one of the sex and mea-
surement time stratified models (i.e. males and females baseline only; males and 
females follow-up only; males both measurements; males baseline only; males 
follow-up only; females both measurements; females baseline only; females 
follow-up only). 
d I.e. FDR < 0.05 after partial correlation analysis adjusted for sex, age, sample 
year, marital status, education, smoking status, physical activity and case- 
control status (n = 248). 
e Refers to long-chain PFAS: PFDA, PFNA and PFUnDA (LC_PFAS) and short- 
chain PFAS: PFHxS, PFOS and PFOA (SC_PFAS). 
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glycerophospholipids and diacylglycerols. 
In the PCA on the 35 metabolite features selected for their associa-
tions with PFAS and diabetes (Supplementary Fig. 2, Supplementary 
Table 5), PC1 and PC2 accounted for the largest proportion of the total 
variance (23% and 12%, respectively) and showed the strongest asso-
ciation with T2D risk, thus these were further investigated. We found 
that metabolite features putatively annotated as glycerophospholipids 
had high loadings in PC2, whereas those annotated as diacylglycerols 
had high loadings in PC1 (Supplementary Table 5, Fig. 4). PFDA, 
PFUnDA and LC_PFAS correlated positively with both PC1 and PC2, 
whereas PFNA correlated only with PC1. PFHxS, PFOS, PFOA and 
SC_PFAS did not correlate with any of the PCs. PC1 furthermore corre-
lated positively with alcohol and fish intake as well as with BMI and 
HOMA-IR and was associated with increased risk of T2D (model 1: OR =
1.9; 95% Confidence Interval (CI) = 1.3–2.7). PC2 correlated negatively 
with BMI and HOMA-IR, but not with any of the dietary intakes and 
associated with lower risk of T2D (model 1: OR = 0.2; 95% CI = 0.1–0.4) 
(Fig. 4). 
Mutual adjustment for PC1 and PC2 did not affect results qualita-
tively (data not shown). Similar associations with T2D were seen in the 
validation cohort (Supplementary Fig. 3). Results did not differ greatly 
between males and females, although males had a slightly higher OR of 
T2D for PC1, whereas females had a higher OR for PC2 (Supplementary 
Fig. 3). 
4. Discussion 
This population-based prospective nested case-control study is the 
first to use metabolomics data to examine the relationship between PFAS 
and risk of T2D, providing valuable information about potential un-
derlying mechanisms. Modelling of PFAS exposures by the metabolome 
in the random forest algorithm resulted in strikingly strong models and 
171 metabolite features associated with PFAS, from which 35 also 
associated with T2D risk. This is more than would be expected by chance 
Fig. 3. Multivariable-adjusted univariate associations between metabolite features and (a) T2D risk (odds ratios per 1-standard deviation increase ± confidence 
interval (CI)) and (b) their correlations with PFAS and food components (missing n = 2). (a) Model 1 was adjusted for matching factors (sex, age and sample year), 
marital status, education, smoking status and physical activity. Model 2 was additionally adjusted for fish, meat and alcohol intake and BMI (missing n = 2). (b) 
Partial Spearman correlations were adjusted for sex, age, sample year, marital status, education, smoking status, physical activity and case-control status and sig-
nificance is indicated by * FDR < 0.05, ** FDR < 0.01, *** FDR < 0.001. Red color represents positive correlations, blue color represents negative correlations. 
Unknown metabolite features are presented as: Mode_m/z@RT. Abbreviations: docosahexaenoic acid (DHA), long-chain PFAS: PFDA, PFNA and PFUnDA (LC_PFAS) 
and short-chain PFAS: PFHxS, PFOS and PFOA (SC_PFAS). (For interpretation of the references to color in this figure legend, the reader is referred to the web version 
of this article.) 
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(n = 2), indicating that most of the 35 features could be involved in 
pathways related to both PFAS and T2D. Such common pathways are of 
interest for the understanding of biological mechanisms behind any 
relationship between PFAS exposures and T2D risk. 
PFAS were, via PCA, assembled into two groups based on their 
measured concentrations in blood, with shorter-chain PFHxS, PFOS and 
PFOA in one group (i.e. SC_PFAS) and long-chain PFNA, PFDA and 
PFUnDA in the other (i.e. LC_PFAS). However, the underlying rationale 
of the observed grouping is uncertain. PFAS could potentially group 
together either due to similarities in exposure sources or to their bio-
logical accumulation and potency (Wolf et al., 2008a). Several lipid- 
related metabolites were associated with individual PFAS congeners or 
PFAS groups. These findings are supported by previous untargeted 
metabolomics studies, which also indicate associations between PFAS (i. 
e. PFHxS, PFOS, PFOA, PFNA, PFDA, PFUnDA) and fatty acids, lipids 
and, in particular, glycerophospholipids (Salihovic et al., 2019; Alderete 
et al., 2019; Kingsley et al., 2019; Hu et al., 2019). The current results 
are further strengthened by the fact that similar PFAS associated me-
tabolites were discovered using different data analytical strategies, i.e. 
univariate analysis (Salihovic et al., 2019; Alderete et al., 2019; Kingsley 
et al., 2019; Hu et al., 2019) versus the multivariate modelling intro-
duced in this work. Although causality cannot be inferred in the present 
study design, a PFAS-related effect on lipids is biologically plausible 
since PFAS are thought to disrupt fat metabolism through several 
mechanisms, e.g. activation of PPARs (Fievet et al., 2006; Berger et al., 
2005), interference with endocrine pathways (Zhao et al., 2010) or 
cholesterol transport (Boujrad et al., 2000; Shi et al., 2010, 2007). 
Unsupervised analysis of the PFAS-associated metabolite features 
showed that one pattern was dominated by annotated glycer-
ophospholipids and the other by diacylglycerols. Both PFAS-related 
metabolite feature patterns correlated with the long-chain PFNA, 
PFDA and PFUnDA, whereas they did not correlate equally strong with 
the shorter PFHxS, PFOS and PFOA. PFDA and PFUnDA were mainly 
associated with the glycerophospholipid metabolites, whereas PFNA 
associated with diacylglycerol metabolites. The stronger associations for 
long-chain PFAS may be explained by a higher potency and biological 
accumulation (Wolf et al., 2008a), supported by a previous finding 
where the strongest associations were also found between long-chain 
PFAS (i.e. PFNA and PFUnDA) and glycerophospholipids as well as 
other fatty acids (e.g. docosapentaenoic acid (DPA) and docosahexae-
noic acid (DHA)) (Salihovic et al., 2019). 
Furthermore, we discovered that the two metabolite feature patterns 
related to long-chain PFAS had opposite associations with T2D risk. The 
glycerophospholipid pattern associated with a decreased risk of T2D, 
whereas the diacylglycerol pattern associated with an increased risk. 
This is in line with a previous plasma lipidomic profiling study that 
Fig. 4. Multivariate associations of PFAS-and T2D-related metabolite features with PFAS, fish and red/processed meat intakes, alcohol consumption, BMI, HOMA-IR 
and risk of T2D. The triplot represents the correlations between metabolite features (features with absolute loading > 0.4 are visualized by black arrows with label, 
whereas with absolute loading < 0.4 are represented by light grey arrows), fish, red/processed meat intakes, alcohol consumption, BMI and HOMA-IR as well as risk 
of T2D (Schillemans et al., 2019). Correlations were calculated using partial Spearman correlation adjusted for sex, age, sample year, case/control status, marital 
status, education, smoking status, physical activity and FDR multiple testing (missing n = 2). Odds ratios per 1 standard deviation increase in pattern score ±95% 
confidence intervals were obtained from two conditional logistic regression models: Model 1 was adjusted for matching factors (sex, age and sample year), marital 
status, education, smoking status and physical activity. Model 2 was additionally adjusted for fish, meat and alcohol intake and BMI (missing n = 2). Unknown 
metabolite features are presented as: Mode_m/z@RT. Abbreviations: docosahexaenoic acid (DHA), long-chain PFAS: PFDA, PFNA and PFUnDA (LC_PFAS) and short- 
chain PFAS: PFHxS, PFOS and PFOA (SC_PFAS). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of 
this article.) 
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showed inverse associations between certain phospholipids, especially 
lyso-phosphatidylcholines, and T2D as well as direct associations be-
tween diacylglycerols and T2D (Razquin et al., 2018). Our results sug-
gest that PFAS are associated with two groups of lipid species with 
opposite relations with T2D development, which could contribute to the 
interpretation of inconsistent results from epidemiological studies 
investigating PFAS exposures and subsequent T2D risk. A prospective 
and a cross-sectional study indicate associations of PFOS and PFOA with 
increased T2D risk (He et al., 2018; Sun et al., 2018), which would be 
supported by the results of the diacylglycerol dominated metabolite 
feature pattern. On the other hand, a few cross-sectional studies show 
lower T2D prevalence with higher serum PFAS (i.e. PFHxS, PFOS, PFOA 
and PFNA) concentrations (MacNeil et al., 2009; Conway et al., 2016). 
Likewise, in this same study population, we previously showed inverse 
prospective associations between PFAS (i.e. PFHxS, PFOS, PFOA, PFNA, 
PFDA and PFUnDA) levels and T2D risk as well as inverse associations 
with insulin resistance and triglycerides in those who were non- 
diabetics, although these were mainly non-significant (Donat-Vargas 
et al., 2019a, 2019b). These findings get support from the results of the 
glycerophospholipid dominated metabolite feature pattern, which also 
shows an inverse correlation with HOMA-IR. Thus, PFAS-related glyc-
erophospholipids may be related to insulin sensitivity and T2D risk. 
Interestingly, glycerophospholipids and diacylglycerols share reactions 
in lipid synthesis pathways (Saltiel and Kahn, 2001). Additionally, 
increased circulating free fatty acids and accumulation of triglycerides 
and fatty acid-derived metabolites (e.g. diacylglycerols) in muscle and 
liver is thought to contribute to insulin resistance (Saltiel and Kahn, 
2001). 
Another potentially interesting PFAS- and T2D-related metabolite 
was identified as GBB, an intermediate metabolite in the carnitine 
biosynthesis and in the gut microbiota-dependent formation of trime-
thylamine N-oxide (Koeth et al., 2019). GBB correlated negatively with 
PFAS and associated inversely with T2D. One possible pathway linking 
PFAS to GBB relates to PPARα activation, as animal studies indicate that 
carnitine metabolism may be regulated by PPARα (Ringseis et al., 2012), 
another speculation is that PFAS affects the gut microbiota. Carnitine 
plays a key role in lipid metabolism and studies indicate both beneficial 
(Strand et al., 2018) and detrimental (Koeth et al., 2014) effects of 
carnitine on T2D due to fatty acid transport and β-oxidation as well as 
trimethylamine N-oxide associated pro-diabetic effects (e.g. inflamma-
tion, insulin resistance and hyperlipidemia) (Li et al., 2015; Dambrova 
and Liepinsh, 2015). Red meat is the main source for carnitine, but there 
was no correlation between GBB and meat or fish, making it unlikely 
that the PFAS-GBB link is confounded by diet. 
Nevertheless, since different dietary habits and different dietary 
sources of PFAS have been suggested to confound the PFAS-T2D asso-
ciation and contribute to the inconsistencies in the epidemiological 
findings (Donat-Vargas et al., 2019a), we further explored correlations 
between other PFAS-related metabolite features and different dietary 
components. In this study, fish intake correlated the strongest with the 
diacylglycerol dominated metabolite feature pattern associated with 
increased T2D risk. For fish intake, literature indicates inverse associa-
tions with T2D (Jannasch et al., 2017), although there are some in-
consistencies (Namazi et al., 2019). Since fish is known to be the main 
dietary source of PFAS as well as of other persistent organic pollutants 
(POPs) and the latter are associated with increased T2D risk (Tornevi 
et al., 2019), we speculate that the positive association between PFAS 
and T2D may be confounded by other POPs. This is supported by our 
previous finding that some of the PFAS-related metabolites including 
diacylglycerol (RP_684.55@805.11) and a known biomarker of fish 
intake DHA (RP_329.25@632.04) were also related to fish intake and 
POPs (Shi et al., 2019b). Although BMI correlated with the PFAS-related 
metabolite feature pattern, adjustment for BMI in the logistic regression 
did not affect the qualitative assessment of risk. This finding suggests 
that the associations between the PFAS-related metabolite features and 
T2D risk were independent of BMI. It is uncertain whether we should 
consider BMI as a confounder or a mediator, as PFAS exposures may 
affect weight and weight regain (Liu et al., 2018; Cardenas et al., 2018). 
Our study fits in a broader perspective of exposome-based studies 
that are using metabolomics in population-based research as a tool to 
investigate the influence of environmental exposures on disease risks 
(Walker et al., 2019). We employed a meet-in-the-middle approach, 
where the exposure is related to intermediate biomarkers (metab-
olomics), which are then connected to disease risk (Vineis and Perera 
et al., 2007; Chadeau-Hyam et al., 2011; Gängler et al., 2019). This 
approach has advantages for causality assessment in epidemiology and 
may be integrated with the toxicological concept of adverse outcome 
pathways. Our study has several strengths. First, the prospective design, 
measurements of PFAS in blood and stringent T2D diagnosis reduced the 
likelihood of reverse causation bias and chances of exposure and 
outcome misclassification, respectively. Second, the collected data 
allowed adjustments for several potential confounders as well as to 
explore the impact of diet on the associations. Finally, the random forest 
modelling was designed to minimize overfitting and false positives while 
selecting all-relevant metabolite features, allowing us to select meta-
bolic features using a multivariate approach. Nevertheless, there are also 
several limitations that need to be acknowledged. First, the explorative 
nature of our study hinders inference regarding possible biomarkers or 
dose-response relations. Our study may also be subject to false-negative 
results, i.e. we may have missed associations between PFAS and 
metabolite features due to stringent inclusion criteria and stratification 
analyses, as well as false-positive results due to chance findings or 
overfitting. However, the hypergeometric test indicated a significant 
enrichment in our results in model 1, but not in model 2, which may be 
due to over-adjustment in model 2. The validation in the second inde-
pendent dataset indicates that overfitting is limited, although the pos-
sibility for residual confounding remains. Second, we focused on 2 PCs 
of 35 PFAS-related metabolite features that explained approximately a 
third of the variance within the data. It is possible that remaining 
variability might be attributed to either residual variability or poten-
tially important but unknown systematic variability. However, the pri-
mary aim of this study was to identify plasma metabolites associated 
with exposure to both PFAS and T2D risk, which were reflected by the 
first 2 PCs and were thus further investigated. There was no opportunity 
to replicate these results in a separate cohort, but similarities in results 
between different metabolomics studies investigating PFAS do 
strengthen the observed findings. Furthermore, not all the discovered 
PFAS-related metabolite features had MS-MS data available and were 
thus only putatively annotated for class, i.e. glycerophospholipids and 
diacylglycerols. There was no possibility to do targeted MS-MS yet, but 
detailed IDs will be included upon targeted examinations. 
In conclusion, we annotated metabolite classes that were associated 
both with baseline PFAS levels and prospective T2D risk in this 
exploratory nested case-control study. These metabolite features formed 
two patterns mainly represented by annotated glycerophospholipid and 
diacylglycerol classes. Although both PFAS-related metabolite feature 
patterns correlated positively with PFAS, they had opposite directions 
on T2D risk, with glycerophospholipids showing inverse associations 
and diacylglycerols showing direct associations. Furthermore, GBB 
correlated negatively with PFAS and associated inversely with T2D. Our 
findings highlight the possibility that PFAS are associated with two 
groups of lipid species with diverging relations with T2D development, 
which could explain the conflicting associations found in literature be-
tween PFAS and T2D risk (Sun et al., 2018; Donat-Vargas et al., 2019a). 
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